The Japanese Association for Thoracic Surgery has conducted annual surveys of thoracic surgery throughout Japan since 1986 to determine the statistics regarding the number of procedures according to operative category. Here, we have summarized the results from our annual survey of thoracic surgery performed during 2014.

Thoracic surgery was classified into three categories---cardiovascular, general thoracic, and esophageal surgery---and the patient data were examined and analyzed for each group. Access to the computerized data is offered to all members of this Association. We honor and value all member's continued kind support and contributions (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}).**Table 1** Questionnaires sent out and received back by the end of December 2015Sent outReturnedResponse rate (%)(A) Cardiovascular surgery57856197.1(B) General thoracic surgery76273296.1(C) Esophageal surgery62660196.0 **Table 2** Categories subclassified according to the number of operations performedNumber of operations performedCategoryCardiovascular surgeryGeneral thoracic surgery021301--24428125--498610850--99157202100--149103137150--1995280≧20010094Total561732Number of operations performedEsophageal surgery0981--41455--911710--1910820--293930--392740--4925≧5042Total601

The incidence of hospital mortality was added to the survey to determine the nationwide status, which has contributed to the Japanese surgeons to understand the present status of thoracic surgery in Japan and to make progress to improve operative results by comparing their work with those of others. The Association was able to gain a better understanding of the present problems as well as the future prospects, which has been reflected to its activity including education of its members. Thirty-day mortality (so-called "operative mortality") is defined as death within 30 days of operation regardless of the patient's geographic location and even though the patient had been discharged from the hospital.

Hospital mortality is defined as death within any time interval after an operation if the patient had not been discharged from the hospital. Hospital-to-hospital transfer is not considered discharge in the categories of cardiovascular surgery and esophageal surgery: transfer to a nursing home or a rehabilitation unit is considered hospital discharge unless the patient subsequently dies of complications of the operation. While hospital-to-hospital transfer after 30 days of operation is considered discharge in the categories of general thoracic surgery, because data of national clinical database (NCD) 2014 were used in this category, and hospital-to-hospital transfer after 30 days of operation is considered discharge in NCD.

Abstract of the survey {#Sec1}
======================

We sent out survey questionnaire forms to the departments of each category in all 1039 institutions (578 cardiovascular, 762 general thoracic, and 626 esophageal) nationwide in early April 2014. The response rates in each category by the end of December 2015 were 97.1, 96.1, and 96.0 %, respectively. This high response rate has been keep throughout recent survey, and more than 96 % response rate in all fields in 2014 survey has to be congratulated.

2014 Final report {#Sec2}
=================

(A) Cardiovascular surgery {#Sec3}
--------------------------

First, we are very pleased with the high response rate to our survey of cardiovascular surgery (97.1 %), which definitely enhances the quality of this annual report. We very much appreciate the enormous effort put into completing the survey at each participating institution.

Figure [1](#Fig1){ref-type="fig"} shows the development of cardiovascular surgery in Japan over the last 28 years. Aneurysm surgery includes only operations for thoracic and thoracoabdominal aortic aneurysm. Pacemaker implantation includes only transthoracic implantation, and transvenous implantation is excluded. The number of pacemaker and assist device implantation operations is not included in the total number of surgical operations. A total of 66,453 cardiovascular operations were performed at 561 institutions during 2014 alone and included 30 heart transplantations, which were restarted in 1999.Fig. 1Cardiovascular surgery. *IHD* ischemic heart disease

The number of operations for congenital heart disease (9269 cases) decreased slightly (1.0 %) compared with that of 2013 (9366 cases), and 2.9 % decrease when compared with the data of 10 years ago (9545 cases in 2004). The number of operations for adult cardiac disease (21,939 cases in valvular heart disease, 17,498 cases in thoracic aortic aneurysm, and 2118 cases for other procedures) increased compared with those of 2013 (0.8, 11.0, and 13.2 %, respectively) except for ischemic heart disease (15,629 cases), which decreased 5.6 % of that in 2013. During the last 10 years, the numbers of operations for adult heart disease increased constantly except for that for ischemic heart disease (73.8 % increase in valvular heart disease, 26.5 % decrease in ischemic heart disease, 114.5 % increase in thoracic aortic aneurysm, and 56.5 % increase in other procedures compared those of 2004). The concomitant coronary artery bypass grafting procedure (CABG) is not included in ischemic heart disease but included in other categories, such as valvular heart disease and thoracic aneurysm in our study, and then, the number of CABG still remained over 20,000 cases per year (20,991 cases) in 2014.

Data for individual categories are summarized in tables through [3](#Tab3){ref-type="table"}, [4](#Tab6){ref-type="table"}, [5](#Tab19){ref-type="table"}, [6](#Tab21){ref-type="table"}, [7](#Tab22){ref-type="table"}, [8](#Tab23){ref-type="table"} and [9](#Tab24){ref-type="table"}.**Table 3** Congenital (total; 9269)(1) CPB (+) (total; 6894)NeonateInfant1--17 years≧18 yearsTotalCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1PDA11 (100.0)01 (100.0)2000100013000171 (5.9)01 (5.9)2Coarctation (simple)1100010000110007000390003 +VSD39000510001200060001080004 +DORV800012001 (8.3)3000000023001 (4.3)5 +AVSD100031 (33.3)01 (33.3)3000100081 (12.5)01 (12.5)6 +TGA9001 (11.1)40003000400020001 (5.0)7 +SV41 (25.0)01 (25.0)800020001000151 (6.7)01 (6.7)8 +Others31 (33.3)01 (33.3)800030001000151 (6.7)01 (6.7)9Interrupt. of Ao (simple)4000100010000000600010 +VSD331 (3.0)03 (9.1)231 (4.3)02 (8.7)90005000702 (2.9)05 (7.1)11 +DORV1000300000000000400012 +Truncus0000000000000000000013 +TGA11 (100.0)01 (100.0)0000120000000131 (7.7)01 (7.7)14 +Others500030002001 (50.0)000010001 (10.0)15Vascular ring00008000200000001000016PS1000100001900091 (11.1)01 (11.1)391 (2.6)01 (2.6)17PAIVS or critical PS18001 (5.6)441 (2.3)01 (2.3)8400060001521 (0.7)02 (1.3)18TAPVR1138 (7.1)015 (13.3)654 (6.2)06 (9.2)5000000018312 (6.6)021 (11.5)19PAPVR ± ASD0000500045001 (2.2)271 (3.7)01 (3.7)771 (1.3)02 (2.6)20ASD2000067001 (1.5)667001 (0.1)4940001248002 (0.2)21Cor triatriatum2000141 (7.1)01 (7.1)110004000311 (3.2)01 (3.2)22AVSD (partial)10007000331 (3.0)01 (3.0)24000651 (1.5)01 (1.5)23AVSD (complete)200010801 (0.9)2 (1.9)670004001 (25.0)18101 (0.6)3 (1.7)24 +TOF or DORV1000111 (9.1)01 (9.1)153 (20.0)03 (20.0)0000274 (14.8)04 (14.8)25 +Others30004001 (25.0)6000900022001 (4.5)26VSD (subarterial)41 (25.0)01 (25.0)100000199000330003361 (0.3)01 (0.3)27VSD (perimemb./muscular)90007423 (0.4)04 (0.5)3532 (0.6)1 (0.3)2 (0.6)7100011755 (0.4)1 (0.1)6 (0.5)28VSD + PS0000150002000030003800029DCRV ± VSD10001600028000200006500030Aneurysm of sinus valsalva000010008000220003100031TOF90001761 (0.6)02 (1.1)212001 (0.5)421 (2.4)02 (4.8)4392 (0.5)05 (1.1)32PA + VSD4000491 (2.0)03 (6.1)92001 (1.1)70001521 (0.7)04 (2.6)33DORV170001063 (2.8)03 (2.8)108002 (1.9)111 (9.1)01 (9.1)2424 (1.7)06 (2.5)34TGA (simple)1028 (7.8)1 (1.0)8 (7.8)13000500010001218 (6.6)1 (0.8)8 (6.6)35 +VSD311 (3.2)01 (3.2)121 (8.3)01 (8.3)80000000512 (3.9)02 (3.9)36 VSD + PS100011001 (9.1)151 (6.7)01 (6.7)6000331 (3.0)02 (6.1)37Corrected TGA300023000401 (2.5)02 (5.0)13000791 (1.3)02 (2.5)38Truncus arteriosus111 (9.1)01 (9.1)22001 (4.5)140002000491 (2.0)02 (4.1)39SV222 (9.1)07 (31.8)2024 (2.0)06 (3.0)2634 (1.5)1 (0.4)8 (3.0)201 (5.0)01 (5.0)50711 (2.2)1 (0.2)22 (4.3)40TA5000441 (2.3)01 (2.3)53001 (1.9)100001121 (0.9)02 (1.8)41HLHS402 (5.0)05 (12.5)1249 (7.3)015 (12.1)601 (1.7)02 (3.3)000022412 (5.4)022 (9.8)42Aortic valve lesion6000141 (7.1)01 (7.1)891 (1.1)01 (1.1)161 (6.3)01 (6.3)1253 (2.4)03 (2.4)43Mitral valve lesion2000281 (3.6)01 (3.6)721 (1.4)02 (2.8)80001102 (1.8)03 (2.7)44Ebstein15003 (20.0)14001 (7.1)34000162 (12.5)02 (12.5)792 (2.5)06 (7.6)45Coronary disease10008000141 (7.1)01 (7.1)22000451 (2.2)01 (2.2)46Others21001 (4.8)461 (2.2)03 (6.5)350009001 (11.1)1111 (0.9)05 (4.5)47Redo VSD000050001300030002100048PS release00001000052000240008600049RV-PA conduit replace0000400054000370009500050Others4001 (25.0)412 (4.9)03 (7.3)97000430001852 (1.1)04 (2.2)Total58928 (4.8)1 (0.2)52 (8.8)229737 (1.6)1 (0.04)63 (2.7)2,95416 (0.5)2 (0.1)31 (1.0)10548 (0.8)011 (1.0)689489 (1.3)4 (0.1)157 (2.3)Values in parenthesis represent mortality %*CPB* cardiopulmonary bypass, *PDA* patient ductus arteriosus, *VSD* ventricular septal defect, *DORV* double outlet right ventricle, *AVSD* atrioventricular septal defect, *TGA* transposition of great arteries, *SV* single ventricle, Interupt. of Ao. interruption of aorta, *PS* pulmonary stenosis, *PA-IVS* pulmonary atresia with intact ventricular septum, *TAPVR* total anomalous pulmonary venous return, *PAPVR* partial anomalous pulmonary venous return, *ASD* atrial septal defect, *TOF* tetralogy of Fallot, DCRV double-chambered right ventricle, *TA* tricuspid atresia, *HLHS* hypoplastic left heart syndrome, *RV-PA* right ventricle-pulmonary artery (2) CPB (−) (total; 2375)NeonateInfant1--17 years≧18 yearsTotalCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1PDA4304 (0.9)05 (1.2)2302 (0.9)04 (1.7)4000020007026 (0.9)09 (1.3)2Coarctation (simple)211 (4.8)01 (4.8)2700040000000521 (1.9)01 (1.9)3 +VSD390001600030001000590004 +DORV9000900000000000180005 +AVSD200010004000000070006 +TGA400010002000100080007 +SV12001 (8.3)80000000000020001 (5.0)8 +Others8000200000000000100009Interrupt. of Ao (simple)2000100010001000500010 +VSD250008000100010003500011 +DORV3000100000000000400012 +Truncus1000000000000000100013 +TGA1001 (100.0)0000000010002001 (50.0)14 +Others1000100000000000200015Vascular ring50008000700000002000016PS1000000030000000400017PAIVS or critical PS251 (4.0)01 (4.0)20001 (5.0)81 (12.5)02 (25.0)0000532 (3.8)04 (7.5)18TAPVR300082 (25.0)02 (25.0)10001000132 (15.4)02 (15.4)19PAPVR ± ASD0000000010001000200020ASD0000000000000000000021Cor triatriatum0000000020000000200022AVSD (partial)1000300020001000700023AVSD (complete)35001 (2.9)7200030000000110001 (0.9)24 +TOF or DORV20007000400000001300025 +Others7000100000000000800026VSD (subarterial)10008000100000001000027VSD (perimemb./muscular)49002 (4.1)107002 (1.9)20002000160004 (2.5)28VSD + PS1000000000000000100029DCRV ± VSD1000100000001000300030Aneurysm of sinus valsalva0000000000000000000031TOF282 (7.1)02 (7.1)88000700010001242 (1.6)02 (1.6)32PA + VSD23000691 (1.4)01 (1.4)231 (4.3)01 (4.3)00001152 (1.7)02 (1.7)33DORV360005500014000000010500034TGA (simple)60006000000000001200035 +VSD70004000300000001400036 VSD + PS12000140001000130004000037Corrected TGA800026000800080005000038Truncus arteriosus151 (6.7)01 (6.7)500050000000251 (4.0)01 (4.0)39SV732 (2.7)04 (5.5)582 (3.4)03 (5.2)2400060001614 (2.5)07 (4.3)40TA25000131 (7.7)01 (7.7)90000000471 (2.1)01 (2.1)41HLHS973 (3.1)07 (7.2)1400016002 (12.5)10001283 (2.3)09 (7.0)42Aortic valve lesion1000200010000000400043Mitral valve lesion2000000000000000200044Ebstein60001000300010001100045Coronary disease100021 (50.0)01 (50.0)4000000071 (14.3)01 (14.3)46Others151 (6.7)01 (6.7)5200056000180001411 (0.7)01 (0.7)47Redo VSD0000000000000000000048 PS release1001 (100.0)2000100000004001 (25.0)49 RV-PA conduit replace0000000000000000000050 Others600022001 (4.5)211 (4.8)01 (4.8)5000541 (1.9)02 (3.7)Total105115 (1.4)028 (2.7)9739 (0.9)016 (1.6)2853 (1.1)06 (2.1)66000237527 (1.1)050 (2.1)Values in parenthesis represent mortality %*CPB* cardiopulmonary bypass, *PDA* patient ductus arteriosus, *VSD* ventricular septal defect, *DORV*double outlet right ventricle, *AVSD* atrioventricular septal defect, *TGA* transposition of great arteries, *SV* single ventricle, Interupt. of Ao. interruption of aorta, *PS* pulmonary stenosis, *PA-IVS* pulmonary atresia with intact ventricular septum, *TAPVR* total anomalous pulmonary venous return, *PAPVR* partial anomalous pulmonary venous return, *ASD* atrial septal defect, *TOF* tetralogy of Fallot, *DCRV* double-chambered right ventricle, *TA* tricuspid atresia, *HLHS* hypoplastic left heart syndrome, *RV-PA* right ventricle-pulmonary artery (3) Main procedureNeonateInfant1--17 years≧18 yearsTotalCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1SP shunt1494 (2.7)08 (5.4)3576 (1.7)09 (2.5)42001 (2.4)100054910 (1.8)018 (3.3)2PAB3877 (1.8)015 (3.9)2632 (0.8)05 (1.9)1100000006619 (1.4)020 (3.0)3Bidirectional Glenn or hemi-Fontan ± α10002402 (0.8)02 (0.8)1061 (0.9)01 (0.9)40003513 (0.9)03 (0.9)4Damus--Kaye--Stansel operation2000361 (2.8)01 (2.8)150003001 (33.3)561 (1.8)02 (3.6)5PA reconstruction/repair (including redo)16001 (6.3)1062 (1.9)03 (2.8)140002 (1.4)250002872 (0.7)06 (2.1)6RVOT reconstruction/repair120001111 (0.9)02 (1.8)2021 (0.5)03 (1.5)53001 (1.9)3782 (0.5)06 (1.6)7Rastelli procedure900039001 (2.6)94002 (2.1)11000153003 (2.0)8Arterial switch procedure1349 (6.7)1 (0.7)9 (6.7)401 (2.5)01 (2.5)21 (50.0)02 (100.0)000017611 (6.3)1 (0.6)12 (6.8)9Atrial switch procedure21 (50.0)01 (50.0)40001000000071 (14.3)01 (14.3)10Double switch procedure000000001500000001500011Repair of anomalous origin of CA10004000800040001700012Closure of coronary AV fistula100050004000290003900013Fontan/TCPC000050003621 (0.3)04 (1.1)300003971 (0.3)04 (1.0)14Norwood procedure29002 (6.9)938 (8.6)017 (18.3)200010001258 (6.4)019 (15.2)15Ventricular septation000010000400010001500016Left side AV valve repair (including Redo)31 (33.3)02 (66.7)452 (4.4)02 (4.4)71000280001473 (2.0)04 (2.7)17Left side AV valve replace (including Redo)00009000372 (5.4)02 (5.4)19000652 (3.1)02 (3.1)18Right side AV valve repair (including Redo)4002 (50.0)14001 (7.1)340003800090003 (3.3)19Right side AV valve replace (including Redo)000021 (50.0)01 (50.0)9000152 (13.3)02 (13.3)263 (11.5)03 (11.5)20Common AV valve repair (including Redo)2000331 (3.0)03 (9.1)342 (5.9)02 (5.9)1000703 (4.3)05 (7.1)21Common AV valve replace (including Redo)100020007001 (14.3)100011001 (9.1)22Repair of supra-aortic stenosis300090001500020002900023Repair of subaortic stenosis (including Redo)2002 (100.0)7000242 (8.3)02 (8.3)7000402 (5.0)04 (10.0)24Aortic valve plasty ± VSD closure400080003100020004500025Aortic valve replacement0000000019000230004200026AVR with annular enlargement000000001200031 (33.3)01 (33.3)151 (6.7)01 (6.7)27Aortic root replace (except Ross)000010001000050001600028Ross procedure00000000111 (9.1)01 (9.1)2000131 (7.7)01 (7.7)Total76222 (2.9)1 (0.1)42 (5.5)144327 (1.9)048 (3.3)132211 (0.8)023 (1.7)3083 (1.0)05 (1.6)383563 (1.6)1 (0.03)118 (3.1)Values in parenthesis represent mortality %*SP* systemic-pulmonary, *PAB* pulmonary artery banding, *PA* pulmonary artery, *RVOT* right ventricular outflow tract, *CA* coronary artery, *AV* fistula arteriovenous fistula, *TCPC* total cavopulmonary connection, *AV* valve atrioventricular valve, *VSD* ventricular septal defect, *AVR* aortic valve replacement **Table 4** Acquired (total, (1) + (2) + (4) + (5) + (6) + (7) + isolated ope. for arrhythmia in (3); 39,485(1) Valvular heart disease (total; 21,939)ValveCasesOperation30-day mortalityHospital mortalityRedoMechanicalBioprosthesisRoss procedureRepairWith CABGHospitalAfter dischargeCases30-day mortalityHospital mortalityReplaceRepairReplaceRepairReplaceRepairHospitalAfter dischargeIsolatedA10,2191884803712972298156 (1.6)5 (1.7)3 (0.03)0238 (2.4)9 (3.0)37120 (5.4)035 (9.4)M4851684918324971656 (3.5)16 (0.5)2 (0.1)095 (5.9)35 (1.1)34410 (2.9)027 (7.8)T2531068175255 (6.4)5 (2.9)009 (11.5)7 (4.0)483 (6.3)06 (12.5)P1329200000004000A + MA1537388108505523875 (4.9)0112 (7.3)9113 (14.3)016 (17.6)M2754220832A + TA44896339166311 (2.5)023 (5.1)422 (4.8)04 (9.5)T350435M + TM35134941044197231353 (1.5)094 (2.7)23413 (5.6)022 (9.4)T12703424A + M + TA105625575903913039 (3.7)064 (6.1)668 (12.1)011 (16.7)M1983810474T41701032Others4952201421 (2.0)02 (0.2)10000Total21,939431013,176212,0063785422 (1.9)5 (0.02)688 (3.1)121069 (5.7)0121 (10.0)Number of redo cases is included in total case number of 21,939Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting,*A* aortic valve,*M* mitral valve,*T* tricuspid valve,*P* pulmonary valve Cases30-day mortalityHospital mortalityHospitalAfter dischargeTAVR87711117 (2) Ischemic heart disease (total, (A) + (B) + (C); 15,629)(*A*)*Isolated CABG* (*total*; (*a*)+(*b*);*14,454*)(a-1) on-pump arrest CABG (total; 3277)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyArterial graft onlyArtery graft + SVGSVG onlyOthersUnclearCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1VD931 (1.1)01 (1.1)192 (10.5)03 (15.8)5001 (20.0)21 (50.0)02 (100.0)551846002VD4613 (0.7)06 (1.3)472 (4.3)02 (4.3)700000009539227013VD151210 (0.7)012 (0.8)16115 (9.3)019 (11.8)151 (6.7)02 (13.3)11 (100.0)01 (100.0)9215691909LMT7618 (1.1)012 (1.6)19011 (5.8)015 (7.9)31 (33.3)01 (33.3)00001078143311Total282722 (0.8)031 (1.1)41730 (7.2)039 (9.4)302 (6.7)04 (13.3)32 (66.7)03 (100.0)3492793125111Kawasaki700010001000000072000Hemodialysis1726 (3.5)08 (4.7)283 (10.7)05 (17.9)1001 (100.0)0000101731008Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting, *1VD* one-vessel disease, *2VD* two-vessel disease, *3VD* three-vessel disease, *LMT* left main trunk, *SVG* saphenous vein graft, *LMT* includes LMT alone or LMT with other branch diseases (a-2) on-pump beating CABG (total; 2171)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyArterial graft onlyArtery graft + SVGSVG onlyOthersUnclearCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1VD352 (5.7)02 (5.7)312 (6.5)05 (16.1)4001 (25.0)31 (33.3)01 (33.3)40625022VD2554 (1.6)06 (2.4)514 (7.8)06 (11.8)111 (9.1)01 (9.1)62 (33.3)04 (66.7)7422418073VD89415 (1.7)028 (3.1)17015 (8.8)018 (10.6)700011 (100.0)01 (100.0)11891824012LMT4796 (1.3)08 (1.7)21624 (11.1)033 (15.3)600021 (50.0)01 (50.0)1035643105Total166327 (1.6)044 (2.6)46845 (9.6)062 (13.2)281 (3.6)02 (7.1)125 (41.7)07 (58.3)335171298026Kawasaki200011 (100.0)01 (100.0)0000100011002Hemodialysis1394 (2.9)011 (7.9)303 (10.0)04 (13.3)60002001 (50.0)171421008Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting, *1VD* one-vessel disease, *2VD* two-vessel disease, *3VD* three-vessel disease, *LMT* left main trunk, *SVG* saphenous vein graft, *LMT* includes LMT alone or LMT with other branch diseases (b) off-pump CABG (total; 9006)(The present section also includes cases of planned off-pump CABG in which, during surgery, the change is made to an on-pump CABG or on-pump beating-heart procedure)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyArterial graft onlyArtery graft + SVGSVG onlyOthersUnclearCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1VD5563 (0.5)06 (1.1)704 (5.7)05 (7.1)271 (3.7)02 (7.4)21 (50.0)01 (50.0)53136640242VD144610 (0.7)1 (0.07)13 (0.9)1448 (5.6)09 (6.3)120002000521977560503VD367927 (0.7)043 (1.2)38613 (3.4)016 (4.1)2200030007083237410104LMT216414 (0.6)023 (1.1)47418 (3.8)023 (4.9)140005000654193445024Total784554 (0.7)1 (0.01)85 (1.1)107443 (4.0)053 (4.9)751 (1.3)02 (2.7)121 (8.3)01 (8.3)241461842060202Kawasaki16000000000000000132100Hemodialysis5244 (0.8)09 (1.7)794 (5.1)04 (5.1)700010009945313046Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting, *1VD* one-vessel disease, *2VD* two-vessel disease, *3VD* three-vessel disease, *LMT* left main trunk, *SVG* saphenous vein graft, *LMT* includes LMT alone or LMT with other branch diseases (c) Includes cases of conversion, during surgery, from off-pump CABG to on-pump CABG or on-pump beating-heart CABG (total; 156)Primary, electivePrimary, emergencyRedo, electiveRedo, emergencyCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeA conversion to on-pump CABG arrest heart271 (3.7)00300000000000A conversion to on-pump beating-heart CABG1004 (4.0)04 (4.0)263 (11.5)03 (11.5)00000000Total1275 (3.9)04 (3.1)293 (10.3)03 (10.3)00000000Hemodialysis151 (6.7)01 (6.7)100000000000Values in parenthesis represent mortality %*CABG* coronary artery bypass grafting (*B*)*Operation for complications of MI* (*total*;*1175*)ChronicAcuteConcomitant operationCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeCABGMVPMVRInfarctectomy or aneurysmectomy2576 (2.3)013 (5.1)386 (15.8)07 (18.4)1645919VSP closure514 (7.8)05 (9.8)24570 (28.6)082 (33.5)7717Cardiac rupture211 (4.8)05 (23.8)19973 (36.7)078 (39.2)2311Mitral regurgitation 1) Papillary muscle rupture101 (10.0)01 (10.0)4610 (21.7)1 (2.2)12 (26.1)181146 2) Ischemic2517 (2.8)017 (6.8)277 (25.9)07 (25.9)22117453Others19000111 (9.1)03 (27.3)340Total60919 (3.1)041 (6.7)566167 (29.5)1 (0.2)189 (33.4)506250126Values in parenthesis represent mortality %Acute, within 2 weeks from the onset of myocardial infarction*MI* myocardial infarction,*CABG* coronary artery bypass grafting,*MVP* mitral valve repair,*MVR* mitral valve replacement,*VSP* ventricular septal perforation (*C*)*TMLR* (*total*;*0*)Cases30-day mortalityHospital mortalityHospitalAfter dischargeIsolated0000With CABG0000Total0000*TMLR* transmyocardial laser revascularization (3) Operation for arrhythmia (total; 3855)Cases30-day mortalityHospital mortalityConcomitant operationIsolatedCongenitalValveIHDOthersMultiple combinationHospitalAfter discharge2 categories3 categoriesMaze348634 (1.0)055 (1.6)151273,16237521644032For WPW20000110000For ventricular tachyarrhythmia352 (5.7)03 (8.6)231413520Others3323 (0.9)04 (1.2)8971935725343Total385539 (1.0)062 (1.6)106138337044524647635Values in parenthesis represent mortality %. Except for 106 isolated cases, all remaining 3749 cases are doubly allocated, one for this subgroup and the other for the subgroup corresponding to the concomitant operations*WPW* Wolff--Parkinson--White syndrome, *IHD* ischemic heart disease (4) Operation for constrictive pericarditis (total; 178)CPB (+)CPB (−)Cases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeTotal10212 (11.8)015 (14.7)76005 (6.6)Values in parenthesis represent mortality %*CPB* cardiopulmonary bypass (5) Cardiac tumor (total; 602)Cases30-day mortalityHospital mortalityConcomitant operationHospitalAfter dischargeAVRMVRCABGOthersBenign tumor5304 (0.8)07 (1.3)10112570 Cardiac myxoma4192 (0.5)02 (0.5)482059 Papillary fibroelastoma46002 (4.3)4217 Rhabdomyoma41 (25.0)01 (25.0)0000 Others611 (1.6)02 (3.3)2144Malignant tumor724 (5.6)1 (1.4)11 (15.3)23211 Primary452 (4.4)03 (6.7)2317 Metastatic272 (7.4)1 (3.7)8 (29.6)0014Values in parenthesis represent mortality %*AVR* aortic valve replacement,*MVR* mitral valve replacement,*CABG* coronary artery bypass grafting (6) HOCM and DCM (total; 211)Cases30-day mortalityHospital mortalityConcomitant operationHospitalAfter dischargeAVRMVRMVPCABGMyectomy1715 (2.9)08 (4.7)110192313Myotomy50001200No-resection141 (7.1)01 (7.1)25160Volume reduction surgery of the left ventricle213 (14.3)04 (19.0)0664Total2119 (4.3)013 (6.2)113324517Values in parenthesis represent mortality %*HOCM* hypertrophic obstructive cardiomyopathy,*DCM* dilated cardiomyopathy,*AVR* aortic valve replacement,*MVR* mitral valve replacement,*MVP* mitral alve repair, *CABG* coronary artery bypass grafting (7) Other open-heart operation (total; 820)Cases30-day mortalityHospital mortalityHospitalAfter dischargeTotal82036 (4.4)042 (5.1)Values in parenthesis represent mortality % **Table 5** Thoracic aortic aneurysm (total; 17,498)(1) Dissection (total; 7733)Replaced siteStanford typeAcuteChronicConcomitant operationRedoABABCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityAVPAVRMVPMVRCABGCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1. Ascending Ao.2787220 (7.9)1 (0.04)267 (9.6)10002347 (3.0)013 (5.6)72 (28.6)02 (28.6)182143571377110 (14.1)014 (19.7)2. Aortic root19742 (21.3)048 (24.4)1000605 (8.3)08 (13.3)1000391813252346 (17.6)08 (23.5)3. Ascending Ao. + Arch1525129 (8.5)0156 (10.2)415 (12.2)08 (19.5)2953 (1.0)010 (3.4)1092 (1.8)05 (4.6)1045210275765 (6.6)08 (10.5)4. Arch + descending Ao.572 (3.5)05 (8.8)165 (31.3)06 (37.5)241 (4.2)02 (8.3)625 (8.1)07 (11.3)00005191 (5.3)02 (10.5)5. Aortic root + Asc. Ao. + Arch12921 (16.3)023 (17.8)0000293 (10.3)08 (27.6)5000241091128171 (5.9)01 (5.9)6. Descending Ao.161 (6.3)01 (6.3)414 (9.8)07 (17.1)632 (3.2)03 (4.8)20811 (5.3)014 (6.7)01001244 (16.7)06 (25.0)7. Thoracoabdominal Ao.2001 (50.0)113 (27.3)04 (36.4)272 (7.4)03 (11.1)1387 (5.1)012 (8.7)00001314 (12.9)05 (16.1)8. Extra-anatomical bypass71 (14.3)01 (14.3)8000300040000000000009. Stent graft\*^a^23318 (7.7)025 (10.7)27711 (4.0)016 (5.8)2324 (1.7)08 (3.4)88318 (2.0)1 (0.1)26 (2.9)85307944 (4.3)04 (4.3) 1) TEVARl^\*b^1058 (7.6)011 (10.5)27211 (4.0)015 (5.5)1701 (0.6)03 (1.8)83516 (1.9)1 (0.1)24 (2.9)00000772 (2.6)02 (2.6) 2) Open stent12810 (7.8)014 (10.9)5001 (20.0)623 (4.8)05 (8.1)482 (4.2)02 (4.2)85307172 (11.8)02 (11.8)  a) With total arch^\*c^12710 (7.9)014 (11.0)4001 (25.0)543 (5.6)05 (9.3)432 (4.7)02 (4.7)85307162 (12.5)02 (12.5)  b) Without total arch^\*d^1000100080005000000001000 3) Unspecified0000000000000000000000000Total4953434 (8.8)1 (0.02)527 (10.6)39628 (7.1)041 (10.4)96727 (2.8)055 (5.7)1,41745 (3.2)1 (0.1)66 (4.7)357491221230636635 (9.6)048 (13.1)Values in parenthesis represent mortality %*Ao* aorta, *AVP* aortic valve repair, *AVR* aortic valve replacement, *MVP* mitral valve repair, *MVR* mitral valve replacement, *CABG* coronary artery bypass grafting, *TEVAR* thoracic endovascular aortic (aneurysm) repairAcute, within 2 weeks from the onset\*a = \*b + \*c + \*d + unspecified (2) Non-dissection (total; 9765)Replaced siteUnrupturedRupturedConcomitant operationRedoCPB (−)Cases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityAVPAVRMVPMVRCABGCases30-day mortalityHospital mortalityCases30-day mortalityHospital mortalityHospitalAfter dischargeHospitalAfter dischargeHospitalAfter dischargeHospitalAfter discharge1. Ascending Ao.136924 (1.8)038 (2.8)364 (11.1)07 (19.4)8287267501711225 (4.1)09 (7.4)--------2. Aortic root102227 (2.6)032 (3.1)358 (22.9)010 (28.6)250698711912112917 (13.2)022 (17.1)--------3. Ascending Ao. + Arch213943 (2.0)075 (3.5)16229 (17.9)4 (2.5)38 (23.5)44181218351905 (5.6)06 (6.7)--------4. Arch + descending Ao.13710 (7.3)014 (10.2)222 (9.1)04 (18.2)01100971 (14.3)02 (28.6)--------5. Aortic root + Asc. Ao. + Arch1202 (1.7)03 (2.5)20002690311210001 (10.0)--------6. Descending Ao.2558 (3.1)012 (4.7)6411 (17.2)017 (26.6)00005164 (25.0)06 (37.5)81 (12.5)01 (12.5)7. Thoracoabdominal Ao.39021 (5.4)028 (7.2)6514 (21.5)020 (30.8)00000243 (12.5)04 (16.7)90008. Extra-anatomical bypass2501 (4.0)00000010023001 (33.3)10001 (10.0)9. Stent graft^\*a^352855 (1.6)3 (0.1)95 (2.7)39446 (11.7)069 (17.5)1214215015911 (6.9)025 (15.7)110023 (2.1)1 (0.1)35 (3.2) 1) TEVAR^\*b^315843 (1.4)3 (0.1)75 (2.4)36342 (11.6)062 (17.1)6110111488 (5.4)022 (14.9)110023 (2.1)1 (0.1)35 (3.2) 2) Open stent37012 (3.2)020 (5.4)314 (12.9)07 (22.6)6131139113 (27.3)03 (27.3)--------  a) With total arch^\*c^2858 (2.8)016 (5.6)231 (4.3)04 (17.4)613113582 (25.0)02 (25.0)--------  b) Without total arch^\*d^854 (4.7)04 (4.7)83 (37.5)03 (37.5)0000431 (33.3)01 (33.3)-------- 3) Unspecified000000000000000000000Total8985190 (2.1)4 (0.04)297 (3.3)780114 (14.6)4 (0.5)165 (21.2)41418671647972156046 (8.2)0 76 (13.6)1,12724 (2.1)1 (0.1)37 (3.3)Values in parenthesis represent mortality %*Ao* aorta, *AVP* aortic valve repair, *AVR* aortic valve replacement, *MVP* mitral valve repair, *MVR* mitral valve replacement, *CABG* coronary artery bypass grafting, *TEVAR* thoracic endovascular aortic (aneurysm) repair\*a = \*b + \*c + \*d + unspecified **Table 6** Pulmonary thromboembolism (total; 171)Cases30-day mortalityHospital mortalityHospitalAfter dischargeAcute11015 (13.6)6 (5.5)19 (17.3)Chronic616 (9.8)06 (9.8)Total17121 (12.3)6 (3.5)25 (14.6)Values in parenthesis represent mortality % **Table 7** Assisted circulation (total; 1679)SitesVADHeart--lung assistDeviceResultsMethodResultsCentrifugalVAS (extra)VAS (implant)Not weanedWeanedPCPSOthersNot weanedWeanedOn goingDeathTransplantAliveDeathsTransplantDeathsTransplantDeathsAlivePost cardiotomy Left2355513 (39.4)0123 (9.1)0 Right20001 (50.0)0100 Biventricle  Right80006 (75.0)021 (12.5)043278259 (50.8)079 (15.5)157  Left730Congestive heart failure Left52419910156 (29.2)6187 (3.6)1 Right61002 (28.6)032 (28.6)0 Biventricle  Right2460316 (53.3)082 (6.7)167661332 (45.0)1111 (15.1)281  Left10164Respiratory failure804035 (29.2)015 (12.5)70Total1327210810994 (30.1)64415 (4.8)21188179626 (45.8)1205 (15.0)508Values in parenthesis represent mortality %*VAD* ventricular assist devise,*VAS* ventricular assist system, extra Extracorporeal VAS, implant Implantable VAS, *PCPS* percutaneous cardiopulmonary support **Table 8** Heart transplantation (total; 30)Cases30-day mortalityHospital mortalityHospitalAfter dischargeHeart transplantation301 (3.3)02 (6.7)Heart and lung transplantation0000Total301 (3.3)02 (6.7)Values in parenthesis represent mortality % **Table 9** Pacemaker + ICD (total; 4923)PacemakerICDVA-VCRTCRTDICDInitial5701,97194245383Exchange45480729116254Unclear00000Total10242778123361637*ICD* implantable cardioverter-defibrillator, *CRTD* cardiac resynchronization therapy devise with incorporated ICD devise

In 2014, 6894 open-heart operations for congenital heart disease were performed with overall hospital mortality of 2.3 %. The number of operations for congenital heart disease was quite steady throughout these 10 years (maximum 7,386 cases in 2006), while overall hospital mortality decreased gradually from that of 3.9 % in 2004. In detail, the most common disease was atrial septal defect (1,248 cases); however, its number deceased to 64.3 % of that in 2004, which might be partially due to the recent development of catheter closure of atrial septal defect in Japan. In the last 10 years, hospital mortality for complex congenital heart disease improved in some anomalies such as, complete atrioventricular septal defect (5.4--1.7 %), tetralogy of Fallot (2.5--1.1 %), transposition of the great arteries with and without ventricular septal defect (9.8--3.9 and 7.1--6.6 %, respectively), single ventricle (8.5--4.3 %), and hypoplastic left heart syndrome (27.7--9.8 %). Right heart bypass surgery is now commonly performed (351 bidirectional Glenn procedures excluding 56 Damus--Kaye--Stansel procedures and 397 Fontan-type procedures including total cavopulmonary connection) with acceptable hospital mortality (1.2 and 1.0 %). Norwood type I procedure was performed in 125 cases with relatively low hospital mortality rate of 15.2 %.

As previously mentioned, the number of operations for valvular heart disease increased by 73.8 % in the last 10 years, and the hospital mortality associated with primary single valve replacement was 2.4 and 5.9 % for the aortic and the mitral position, while that for primary mitral valve repair was 1.1 %. However, hospital mortality rate for redo valve surgery was still high and was 9.4 and 7.8 % for aortic and mitral procedure, respectively. Finally, overall hospital mortality did not show dramatic improvement during the last 10 years (3.8 % in 2004 and 3.1 % in 2014), which might be partially due to the recent progression of age of the patients. Repair of the valve became popular procedure (397 cases in the aortic, 6527 cases in the mitral, and 5066 cases in the tricuspid), and mitral valve repair constituted 29.8 % of all valvular heart disease operation and 59.6 % of all mitral valve procedure (10,957 procedures), which are similar to those of the last 5 years and increased compared with those of 2004 (23.6 and 42.8 %, respectively). Aortic and mitral valve replacements with bioprosthesis were performed in 10,220 cases and 2,765 cases, respectively, with the number consistently increasing in the aortic position. The ratio of prostheses changed dramatically during the last 10 years and the usage of bioprosthesis is 77.5 % at the aortic position (36.7 % in 2004) and 25.2 % at the mitral position (14.8 % in 2004). CABG as a concomitant procedure performed in 17.3 % of operations for all valvular heart disease (13.3 % in 2004).

Isolated CABG was performed in 14,454 cases which were only 72.5 % of that of 10 years ago (2004). Among these 14,454 cases, off-pump CABG was intended in 9,006 cases (62.3 %) with a success rate of 98.3 %, so final success rate of off-pump CABG was 61.2 %. The percentage of intended off-pump CABG reached 60.3 % in 2004, and then was kept over 60 % until now. In 14,454 isolated CABG patients, 95.4 % of them received at least one arterial graft, while all arterial graft CABG was performed only 21.4 % of them.

The operative and hospital mortality rates associated with primary elective CABG procedures in 12335 cases were 0.8 and 1.3 %, respectively. Similar data analysis of CABG, including primary/redo and elective/emergency data, was begun in 2003, and the operative and hospital mortality rates associated with primary elective CABG procedures in 2003 were 1.0 and 1.5 %, respectively, so operative results of primary CABG has been stable, while hospital mortality of primary emergency CABG in 1,959 cases was still high and was 7.9 %. During these 10 years, the results of conversion from off-pump CABG improved both in conversion rate (3.1--1.7 %) and in hospital mortality (10.4--4.5 %).

A total of 1175 patients underwent surgery for complications of myocardial infarction, including 329 operations for a left ventricular aneurysm or ventricular septal perforation or cardiac rupture and 261 operations for ischemic mitral regurgitation.

Operations for arrhythmia were performed mainly as a concomitant procedure in 3855 cases with satisfactory mortality (1.6 % hospital mortality) including 3,486 MAZE procedures. MAZE procedure has become quite popular procedure when compared with that in 2004 (1837 cases).

Operations for thoracic aortic dissection were performed in 7733 cases. For 4953 Stanford type A acute aortic dissections, hospital mortality remained high and was 10.6 %. Operations for a non-dissected thoracic aneurysm were carried out in 9765 cases, with overall hospital mortality of 4.7 %. The hospital mortality associated with unruptured aneurysm was 3.3 %, and that of ruptured aneurysm was 21.2 %, which remains markedly high.

The number of stent graft procedures remarkably increased recently. A total of 1,625 patients with aortic dissection underwent stent graft placement: thoracic endovascular aortic repair (TEVAR) in 1,382 cases and open stent grafting in 243 cases. The number of TEVAR for type B chronic aortic dissections increased from 69 cases in 2004 to 835 cases in 2014. The hospital mortality rates associated with TEVAR for type B aortic dissection were 5.5 % in acute cases and 2.9 % for chronic cases, respectively.

A total of 3922 patients with non-dissected aortic aneurysm underwent stent graft placement; TEVAR in 3521 cases (12.4 % increase compared with that in 2013) and open stent grafting in 401 cases (145 % increase compared with that in 2013). The reason of dramatic increase in open stent grafting might be due to commercially availability since 2014. The hospital mortality rates for TEVAR were 2.4 and 17.1 % for non-ruptured and ruptured aneurysm, respectively.

In summary, the total cardiovascular operations increased during 2014 by 1141 cases with steadily improving results in almost all categories throughout these 10 years.

(B) General thoracic surgery {#Sec4}
----------------------------

The total number of operations reported in 2014 in general thoracic surgery has reached 77070, which means 1.74-fold of that in 2001, and increased by 1764 cases compared with that in 2013 (Fig. [2](#Fig2){ref-type="fig"}, Table [10](#Tab25){ref-type="table"}).Fig. 2General thoracic surgery **Table 10** Total entry cases of general thoracic surgery during 2014Cases%Benign pulmonary tumor21712.8Primary lung cancer38,08549.4Other primary malignant pulmonary tumor3590.5Metastatic pulmonary tumor805710.5Tracheal tumor1180.2Mesothelioma6730.9Chest wall tumor6980.9Mediastinal tumor46856.1Thymectomy for MG without thymoma1880.2Inflammatory pulmonary disease22873.0Empyema26083.4Bullous disease excluding pneumothorax4150.5Pneumothorax14,57218.9Chest wall deformity2170.3Diaphragmatic hernia including traumatic550.1Chest trauma excluding diaphragmatic hernia3940.5Lung transplantation600.1Others14281.9Total77,070100.0

The number of operations for primary lung cancer was 38085 in 2014 (Table [10](#Tab25){ref-type="table"}), showing the steady increase (31,301; 2009, 32,801; 2010, 33,878; 2011, 35,667; 2012, 37,008; 2013), and 1.95-fold of the number of operations in 2001. Surgery for lung cancer consists 49.4 % of all the general thoracic surgery.

Surgery for benign pulmonary tumor was 2171 in 2014 (Table [11](#Tab26){ref-type="table"}).**Table 11**1. Benign pulmonary tumorCases30-day mortalityHospital mortalityHospitalAfter dischargeHamartoma481000Sclerosing hemangioma103000Papilloma18000Mucous gland adenoma bronchial7000Fibroma129000Lipoma6000Neurogenic tumor17000Clear cell tumor2000Leiomyoma19000Chondroma5000Inflammatory myofibroblastic tumor1000Pseudolymphoma32000Histiocytosis23000Teratoma0000Others13282 (0.2)1 (0.1)6 (0.5)Total21712 (0.1)1 (0.05)6 (0.3)Values in parenthesis represent mortality %

Further information of primary malignant pulmonary tumors is shown in Tables [12](#Tab27){ref-type="table"} and [13](#Tab28){ref-type="table"}. Among lung cancer subtypes, adenocarcinoma comprises an overwhelming percentage of 69.2 % of the total lung cancer surgery, followed by squamous cell carcinoma of 19.3 %. Limited resection by wedge resection or segmentectomy was performed in 9581 lung cancer patients, which is 25.2 % of the entire cases. Lobectomy was performed in 27,584 patients, which is 72.4 % of the entire cases. Sleeve lobectomy was done in 471 patients. Pneumonectomy was done in 521 patients which is 1.4 % of the entire cases.**Table 12**2. Primary malignant pulmonary tumorCases30-day mortalityHospital mortalityHospitalAfter discharge2. Primary malignant pulmonary tumor38,444104 (0.3)59 (0.2)269 (0.7)Lung cancer38,085103 (0.3)59 (0.2)266 (0.7) Adenocarcinoma26,33833 (0.1)23 (0.1)82 (0.3) Squamous cell carcinoma736746 (0.6)22 (0.3)127 (1.7) Large cell carcinoma8355 (0.6)6 (0.7)10 (1.2) (*LCNEC*)*4624* (0.9)*1* (0.2)*8* (1.7) Small cell carcinoma6011 (0.2)1 (0.2)9 (1.5) Adenosquamous carcinoma5487 (1.3)014 (2.6) Carcinoma with pleomorphic, sarcomatoid or sarcomatous elements5286 (1.1)2 (0.4)12 (2.3) Carcinoid198000 Carcinomas of salivary-gland type45000 Unclassified552 (3.6)04 (7.3) Multiple lung cancer12271 (0.1)3 (0.2)6 (0.5) Others3432 (0.6)2 (0.6)2 (0.6) Wedge resection54384 (0.1)4 (0.1)20 (0.4) Segmental excision41432 (0.05)3 (0.1)13 (0.3) (*Sleeve segmental excision*)*16000* Lobectomy27,58482 (0.3)51 (0.2)198 (0.7) (*Sleeve lobectomy*)*4715* (1.1)*7* (1.5)*10* (2.1) Pneumonectomy5218 (1.5)020 (3.8) (*Sleeve pneumonectomy*)*13001* (7.7) Other bronchoplasty462 (4.3)02 (4.3) Pleuropneumonectomy1000Others3435 (1.5)1 (0.3)10 (2.9)Sarcoma40000AAH126000Others1931 (0.5)03 (1.6)Values in parenthesis represent mortality % **Table 13** Details of lung cancer operationCasesc-Stage (TNM) Ia22,809 Ib7213 IIa2982 IIb1780 IIIa2505 IIIb204 IV481 NA111 Total38,085Sex Male23,540 Female14,516 NA29 Total38,085Cause of death Cardiovascular23 Pneumonia47 Pyothorax4 Bronchopleural fistula16 Respiratory failure41 Pulmonary embolism11 Interstitial pneumonia78 Brain infarction or bleeding14 Others80 Unknown11 Total325p-Stage 0 (pCR)295 Ia19,666 Ib7601 IIa3213 IIb2087 IIIa3761 IIIb179 IV1072 NA211 Total38,085Age \<2085 20--2933 30--39219 40--491009 50--593646 60--6912,731 70--7915,765 80--894532 ≥9058 NA7 Total38,085

There were 103 patients who died without discharge within 30 days after lung cancer surgery, and 59 patients who were discharged from hospital but died within 30 days after lung cancer surgery, indicating that 162 patients died within 30 days after lung cancer surgery (30-day mortality rate; 0.42 %). There were 266 patients died without discharge (hospital mortality rate; 0.70 %). 30-day mortality rate in regard to procedures is 0.12 % in segmentectomy, 0.48 % in lobectomy, and 1.53 % in pneumonectomy. Interstitial pneumonia was the leading cause of death after lung cancer surgery, followed by pneumonia, respiratory failure, cardiovascular event, and bronchopleural fistula.

Surgery for metastatic pulmonary tumors is denoted in Table [14](#Tab29){ref-type="table"}. The number of patients undergoing operations for metastatic pulmonary tumor was 8057 in 2014 with steady increase similarly to lung cancer surgery (6248; 2009, 6748: 2010, 7210; 2011, 7403; 2012, 7829; 2013). Colorectal cancer was by far the leading primary malignancy indicated for resection of metastatic tumors, which comprises 48.4 % of the entire cases.**Table 14**3. Metastatic pulmonary tumorCases30-day mortalityHospital mortalityHospitalAfter discharge3. Metastatic pulmonary tumor805717 (0.2)8 (0.1)30 (0.4) Colo-rectal39022 (0.1)05 (0.1) Hepatobiliary/pancreatic3882 (0.5)02 (0.5) Uterine387000 Mammary445000 Ovarian56000 Testicular84000 Renal6183 (0.5)2 (0.3)3 (0.5) Skeletal14801 (0.7)0 Soft tissue23501 (0.4)2 (0.9) Otorhinolaryngological4222 (0.5)1 (0.2)2 (0.5) Pulmonary4978 (1.6)1 (0.2)11 (2.2) Others87502 (0.2)5 (0.6)Values in parenthesis represent mortality %

118 tracheal tumors were operated in 2014 (Table [15](#Tab30){ref-type="table"}). Squamous cell carcinoma and adenoid cystic carcinoma were frequent primary tracheal tumor.**Table 15**4. Tracheal tumorCases30-day mortalityHospital mortalityHospitalAfter discharge4. Tracheal tumor1184 (3.4)1 (0.8)10 (8.5)(A) Primary malignant tumor (histological classification) Squamous cell carcinoma15001 (6.7) Adenoid cystic carcinoma9000 Mucoepidermoid carcinoma2000 Others10000 Total36001 (2.8)(B) Metastatic/invasive malignant tumor, e.g. invasion of thyroid cancer484 (8.3)1 (2.1)9 (18.8)(C) Benign tracheal tumor (histological classification) Papilloma0000 Adenoma3000 Neurofibroma1000 Chondroma0000 Leiomyoma3000 Others27000 Histology unknown0000 Total34000Operation Sleeve resection with reconstruction13001 (7.7) Wedge with simple closure0000 Wedge with patch closure0000 Total laryngectomy with tracheostomy0000 Others29000 Unknown0000 Total42001 (2.4)Values in parenthesis represent mortality %

673 tumors of the pleural origin were operated in 2014 (Table [16](#Tab31){ref-type="table"}). Diffuse malignant pleural mesothelioma was the most frequent histology. Total pleurectomy was performed in 73 patents and surpassed extrapleural pneumonectomy which was the most frequently chosen operative method in 2013. Hospital mortality rate was 4.1 % after total pleurectomy and 4.3 % after extrapleural pneumonectomy in 2014.**Table 16**5. Tumor of pleural originCases30-day mortalityHospital mortalityHospitalAfter dischargeHistological classification Solitary fibrous tumor122000 Diffuse malignant pleural mesothelioma2833 (1.1)010 (3.5) Localized malignant pleural mesothelioma26001 (3.8) Others2423 (1.2)2 (0.8)9 (3.7) Total6736 (0.9)2 (0.3)20 (3.0)Operative procedure Extrapleural pneumonectomy701 (1.4)03 (4.3) Total pleurectomy731 (1.4)03 (4.1) Others1401 (0.7)04 (2.9) Total2833 (1.1)010 (3.5)Values in parenthesis represent mortality %

698 chest wall tumors were resected in 2014 (Table [17](#Tab32){ref-type="table"}). 362 cases (51.9 %) were benign. Among 336 malignant chest wall tumors, 208 cases (61.9 %) were metastatic tumors.**Table 17**6. Chest wall tumorCases30-day mortalityHospital mortalityHospitalAfter dischargePrimary malignant tumor1281 (0.8)05 (3.9)Metastatic malignant tumor20801 (0.5)3 (1.4)Benign tumor362000Total6981 (0.1)1 (0.1)8 (1.1)Values in parenthesis represent mortality %

Table [18](#Tab33){ref-type="table"} denotes surgery for mediastinal tumors. 4685 mediastinal tumors were operated in 2014. There were 2104 thymic epithelial tumors (1773 thymomas, 296 thymic carcinomas, and 35 thymic neuroendocrine carcinoma including carcinoid), followed by 932 congenital cysts, 481 neurogenic tumors, 214 lymphatic tumors, and 122 germ cell tumors.**Table 18**7. Mediastinal tumorCases30-day mortalityHospital mortalityHospitalAfter discharge7. Mediastinal tumor46855 (0.1)2 (0.04)17 (0.4) Thymoma\*17735 (0.3)09 (0.5) Thymic cancer296001 (0.3) Thymus carcinoid35000 Germ cell tumor122000  *Benign87000*  *Malignant35000* Neurogenic tumor481000 Congenital cyst93201 (0.1)5 (0.5) Goiter75001 (1.3) Lymphatic tumor214000 Excision of pleural recurrence of thymoma43000 Thymolipoma14000 Others70001 (0.1)1 (0.1)Values in parenthesis represent mortality %\* Includes those with myasthenia gravis

Thymectomy for myasthenia gravis was done in 495 patients (Table [19](#Tab34){ref-type="table"}). Among them, 307 patients were associated with thymoma, and the remaining 188 patients were not associated with thymoma.**Table 19**8. Thymectomy for myasthenia gravisCases30-day mortalityHospital mortalityHospitalAfter discharge8. Thymectomy for myasthenia gravis4951 (0.2)01 (0.2) With thymoma3071 (0.3)01 (0.3)Values in parenthesis represent mortality %

Lung resection for inflammatory lung diseases were done in 2287 patients in 2014 (Table [20](#Tab35){ref-type="table"}). Inflammatory pseudotumor comprised 24.7 % of the entire cases, followed by atypical mycobacterium infection (21.9 %) and fungal infections (15.1 %).**Table 20**9. Operation for non-neoplastic disease(A) Inflammatory pulmonary diseaseCases30-day mortalityHospital mortalityHospitalAfter discharge9. Operation for non-neoplastic disease21,976197 (0.9)14 (0.1)425 (1.9)(A) Inflammatory pulmonary disease22876 (0.3)2 (0.1)17 (0.7) Tuberculous infection73000 Mycobacterial infection5011 (0.2)1 (0.2)3 (0.6) Fungal infection3451 (0.3)1 (0.3)6 (1.7) Bronchiectasis67001 (1.5)  Tuberculous nodule133000  Inflammatory pseudo tumor566000  Interpulmonary lymph node63000 Others5394 (0.7)07 (1.3)Values in parenthesis represent mortality %

2,608 operations for empyema were reported in 2014 (Table [21](#Tab36){ref-type="table"}). There were 1911 patients (73.3 %) with acute empyema and 698 patients with chronic empyema. Bronchopleural fistula was associated in 469 patients (24.5 %) with acute empyema and 345 patients (49.5 %) with chronic empyema. It should be noted that hospital mortality was as high as 15.1 % in patients of acute empyema with fistula.**Table 21**9. Operation for non-neoplastic disease(B) EmpyemaCases30-day mortalityHospital mortalityHospitalAfter dischargeAcute empyema191152 (2.7)3 (0.2)126 (6.6) With fistula46928 (6.0)1 (0.2)71 (15.1) Without fistula142523 (1.6)2 (0.1)52 (3.6) Unknown171 (5.9)03 (17.6)Chronic empyema69714 (2.0)1 (0.1)38 (5.5) With fistula34512 (3.5)1 (0.3)27 (7.8) Without fistula3282 (0.6)010 (3.0) Unknown24001 (4.2)Total260866 (2.5)4 (0.2)164 (6.3)Values in parenthesis represent mortality %

Operation for descending necrotizing mediastinitis was done in 103 patients in 2014 (Table [22](#Tab37){ref-type="table"}). Hospital mortality rate was 8.7 %.

Operation for bullous diseases was done in 415 patients in 2014 (Table [23](#Tab38){ref-type="table"}). Lung volume reduction surgery was done in only 28 patients, while emphysematous bulla was the principal target of operation.**Table 22**9. Operation for non-neoplastic disease(C) Descending necrotizing mediastinitisCases30-day mortalityHospital mortalityHospitalAfter discharge(C) Descending necrotizing mediastinitis1036 (5.8)09 (8.7)Values in parenthesis represent mortality % **Table 23**9. Operation for non-neoplastic disease(D) Bullous diseaseCases30-day mortalityHospital mortalityHospitalAfter discharge(D) Bullous disease4151 (0.2)01 (0.2) Emphysematous bulla3221 (0.3)01 (0.3) Bronchogenic cyst18000 Emphysema with volume reduction surgery28000 Others47000Values in parenthesis represent mortality %*LVRS* lung volume reduction surgery

14,572 operations for pneumothorax were reported in 2014 (Table [24](#Tab39){ref-type="table"}).**Table 24**9. Operation for non-neoplastic disease(E) PneumothoraxCases30-day mortalityHospital mortalityHospitalAfter discharge(E) Pneumothorax14,57260 (0.4)8 (0.1)133 (0.9)*Spontaneous pneumothorax* Operative procedure  Bullectomy34103 (0.1)012 (0.4)  Bullectomy with additional procedure76252 (0.03)1 (0.01)7 (0.1)  Coverage with artificial material72412 (0.03)06 (0.1)  Parietal pleurectomy51001 (2.0)  Coverage and parietal pleurectomy92000  Others24101 (0.4)0Others9058 (0.9)012 (1.3)Unknown8000Total11,94813 (0.1)1 (0.01)31 (0.3)*Secondary pneumothorax* Associated disease  COPD176318 (1.0)2 (0.1)51 (2.9)  Tumorous disease847 (8.3)3 (3.6)14 (16.7)  Catamenial148000  LAM47000  Others (excluding pneumothorax by trauma)58222 (3.8)2 (0.3)37 (6.4)  Unknown Operative procedure  Bullectomy3722 (0.5)1 (0.3)3 (0.8)  Bullectomy with additional procedure150916 (1.1)2 (0.1)37 (2.5)   Coverage with artificial material142316 (1.1)2 (0.1)37 (2.6)   Parietal pleurectomy9000   Coverage and parietal pleurectomy18000   Others59000  Others73529 (3.9)4 (0.5)62 (8.4)  Unknown8000  Total262447 (1.8)7 (0.3)102 (3.9)Values in parenthesis represent mortality %

The number of operations for spontaneous pneumothorax was 11,948. Among them, 3410 patients (28.5 %) underwent bullectomy alone, while additional procedure was performed in 7625 patients (63.8 %).

The number of operations for secondary pneumothorax was 2624. COPD was by far the most prevalent associated disease (67.2 %). It should be noted that hospital mortality rate of operation for pneumothorax associated with tumorous disease was as high as 16.7 %.

217 cases of surgery for chest wall deformity were reported in 2014 survey (Table [25](#Tab40){ref-type="table"}). This number might be underestimated compared with the real number of operations, because chest wall deformity is more likely to be treated in the institutes which are not associated with JATS.**Table 25**9. Operation for non-neoplastic disease(F) Chest wall deformityCases30-day mortalityHospital mortalityHospitalAfter discharge(F) Chest wall deformity217000 Funnel chest209000 Others8000

Diaphragmatic hernia was treated by surgery in 55 patients in 2014 (Table [26](#Tab41){ref-type="table"}).**Table 26**9. Operation for non-neoplastic disease(G) Diaphragmatic herniaCases30-day mortalityHospital mortalityHospitalAfter discharge(G) Diaphragmatic hernia551 (1.8)01 (1.8) Congenital22000 Traumatic9000 Others241 (4.2)01 (4.2)Values in parenthesis represent mortality %

Chest trauma was treated by surgery in 394 patients in 2014 (Table [27](#Tab42){ref-type="table"}).**Table 27**9. Operation for non-neoplastic disease(H) Chest traumaCases30-day mortalityHospital mortalityHospitalAfter discharge(H) Chest trauma39429 (7.4)036 (9.1)Values in parenthesis represent mortality %

Table [28](#Tab43){ref-type="table"} denotes operations for other diseases, including 77 arteriovenous malformations and 104 pulmonary sequestrations.**Table 28**9. Operation for non-neoplastic disease(I) Other respiratory surgeryCases30-day mortalityHospital mortalityHospitalAfter discharge(I) Other respiratory surgery132528 (2.1)064 (4.8) Arteriovenous malformation\*77000 Pulmonary sequestration104000 Postoperative bleeding air leakage38611 (2.8)030 (7.8) Chylothorax651 (1.5)02 (3.1) Others69316 (2.3)032 (4.6)Values in parenthesis represent mortality %

Table [29](#Tab44){ref-type="table"} denotes lung transplantation in 2014. A total of 60 lung transplantations were performed in 2014. The number of patients undergoing lung transplantation from brain-dead donors and living-related donors was 40 and 20, respectively. The number of lung transplantation is almost constant these several years, and lung transplantation is still dependent on living-related donors in Japan.**Table 29**10. Lung transplantationCases30-day mortalityHospital mortalityHospitalAfter dischargeSingle lung transplantation from brain dead donor23000Bilateral lung transplantation from brain dead donor17000Lung transplantation from living donor20002 (10.0)Total of lung transplantation60002 (3.3)Donor of living donor lung transplantation37000Values in parenthesis represent mortality %

Details of tracheabronchoplasty, pediatric surgery, and combined resection of neighboring organs are denoted in Tables [30](#Tab45){ref-type="table"}, [31](#Tab46){ref-type="table"}, [32](#Tab47){ref-type="table"}, and [33](#Tab48){ref-type="table"}.**Table 30**11. TracheobronchoplastyCases30-day mortalityHospital mortalityHospitalAfter discharge11. Tracheobronchoplasty6499 (1.4)7 (1.1)16 (2.5)Trachea27001 (3.7) Sleeve resection with reconstruction20001 (5.0) Wedge with simple closure0000 Wedge with patch closure0000 Total laryngectomy with tracheostomy0000 Others7000Carinal reconstruction282 (7.1)02 (7.1)Sleeve pneumonectomy15001 (6.7)Sleeve lobectomy4765 (1.1)7 (1.5)10 (2.1)Sleeve segmental excision22000Bronchoplasty without lung resection131 (7.7)01 (7.7)Others681 (1.5)01 (1.5)Values in parenthesis represent mortality % **Table 31**12. Pediatric surgeryCases30-day mortalityHospital mortalityHospitalAfter discharge12. Pediatric surgery5803 (0.5)07 (1.2)Values in parenthesis represent mortality % **Table 32**13. Combined resection of neighboring organ(s)Organ resectedCases30-day mortalityHospital mortalityHospitalAfter discharge13. Combined resection of neighboring organ(s)14087 (0.5)3 (0.2)25 (1.8)(A) Primary lung cancer (organ resected) Aorta16001 (6.3) Superior vena cava26002 (7.7) Brachiocephalic vein131 (7.7)01 (7.7) Pericardium1431 (0.7)1 (0.7)4 (2.8) Pulmonary artery1581 (0.6)02 (1.3) Left atrium30000 Diaphragm51000 Chest wall (including ribs)3603 (0.8)2 (0.6)17 (4.7) Vertebra161 (6.3)02 (12.5) Esophagus9000 Total8227 (0.9)3 (0.4)29 (3.5)(B) Mediastinal tumor (organ resected) Aorta2001 (50.0) Superior vena cava59001 (1.7) Brachiocephalic vein89000 Pericardium3402 (0.6)03 (0.9) Pulmonary artery3000 Left atrium0000 Diaphragm34001 (2.9) Chest wall (including ribs)9000 Vertebra13000 Esophagus4000 Lung461000 Total10142 (0.2)06 (0.6)Values in parenthesis represent mortality % **Table 33**14. Operation of lung cancer invading the chest wall of the apexCases30-day mortalityHospital mortalityHospitalAfter discharge14. Operation of lung cancer invading the chest wall of the apex7372 (0.3)5 (0.7)15 (2.0)Values in parenthesis represent mortality %Includes tumors invading the anterior apical chest wall and posterior apical chest wall (superior sulcus tumor, so-called Pancoast type)

Committee for Scientific Affairs in JATS changed the method of surveying general thoracic surgery in 2014. JATS had investigated the number of diseases and operative procedures based on questionnaires until 2013 surveys, but JATS started to collect the number of procedures in general thoracic surgery using the database in National Clinical Database (NCD) registry. There were some differences in definition in VATS procedure between surveys by JATS before 2013 and that using NCD after 2014. While the length of skin incision in definition of VATS procedure had been less than 8 cm by JATS survey before 2013 following Swanson et al's proposal \[[@CR1]\], NCD registry did not limit the length of skin incision in VATS procedures. On the other hand, NCD required the surgeons to choose the approach among complete VATS procedure without thoracotomy, the procedure using both thoracotomy and VATS which includes hybrid approach, and conventional thoracotomy without VATS procedure. It is presumed that hybrid approach was included in VATS procedure as far as the skin incision was shorter than 8 cm in JATS survey before 2013, but this does not seem to apply to survey in 2014 based on NCD registry, suggesting possible inconsistency in comparison between JATS survey before 2013 and NCD 2014 registry. In this report, therefore, analysis with regard to VATS procedure was not conducted.

(C) Esophageal surgery {#Sec5}
----------------------

During 2014 alone, a total of 13,958 patients with esophageal diseases were registered from 601 institutions (response rate: 96.0 %) which affiliated to the Japanese Association for Thoracic Surgery and/or to the Japan Esophageal Society. Among these institutions, those where 20 or more patients underwent esophageal surgeries within the year of 2014 were 133 institutions (22.1 %), which shows no definite shift of esophageal operations to high volume institutions when compared to the data of 2013 (33.3 %) (Table [34](#Tab49){ref-type="table"}) Of 3,956 patients with a benign esophageal disease, 1660 (42.0 %) patients underwent surgery, and 57 (1.4 %) patients underwent endoscopic resection, while 2239 (56.6 %) patients did not undergo any surgical treatment. (Table [35](#Tab50){ref-type="table"}) Of 10,638 patients with a malignant esophageal tumor, 8135 (76.5 %) patients underwent resection, esophagectomy for 6247 (59.0 %) and endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) for 1851 (17.5 %), while 2492 (23.5 %) patients did not undergo any resection. (Tables [36](#Tab51){ref-type="table"}, [37](#Tab52){ref-type="table"}) The patients registered, particularly those undergoing ESD or EMR for a malignant esophageal disease, have been increasing since 1990 (Fig. [3](#Fig3){ref-type="fig"}).**Table 34** Distribution of number of esophageal operations in 2014 in each institutionEsophageal surgeryNumber of operations in 2014Benign esophageal diseasesMalignant esophageal diseaseBenign + malignant*0*289136981--42451481455--94512011710--19178110820--293363930--391232740--4902025≧5013742Total601601601 **Table 35** Benign esophageal diseasesOperation (+)Endoscopic resectionOperation (−)TotalNumber of patientsHospital mortalityTotalOpenT/L\*3Open SurgeryT/L\*3Total\~30 days31--90 daysTotal (including after 91 days mortality)\~30 days31--90 daysTotal (including after 91 days mortality)1. Achalasia3381791591 (0.6)01 (0.6)0001 (0.3)523902. Benign tumor111733800000004318172 (1) Leiomyoma704327000000017996 (2) Cyst127500000000012 (3) Others29236000000026661 (4) Not specified00000000000333. Diverticulum553916000000017724. Hiatal hernia7394233162 (0.5)2 (0.5)4 (0.9)1 (0.3)1 (0.3)2 (0.6)6 (0.8)1939325. Spontaneous rupture of the esophagus958784 (4.6)1 (1.1)5 (5.7)0005 (5.3)131086. Esophagotracheal fistula18171000000012307. Congenital esophageal atresia5147401 (2.1)1 (2.1)0001 (2.0)1528. Congenital esophageal stenosis109100000004149. Corrosive stricture of the esophagus11830000000102110. Esophagitis, esophageal ulcer87612600000001199128611. Esophageal varices706732 (3.0)02 (3.0)0002 (2.9)685755 (1) Laparotomy96300000009 (2) Sclerotherapy201201 (3) EVL34434412. Others7562135 (8.1)05 (8.1)0005 (6.7)1435124Total1660107258814 (1.3)4 (0.4)18 (1.7)1 (0.2)1 (0.2)2 (0.3)20 (1.2)5722393956Values in parenthesis represent mortality %*T/L* thoracoscopic and/or laparoscopic **Table 36** Malignant esophageal diseases (histologic classification)Resection (+)Resection (−)TotalCarcinomas8100249510,595 1. Squamous cell carcinoma723323559588 2. Basaloid (-squamous) carcinoma79281 3. Carcinosarcoma43346 4. Adenocarcinoma in the Barrett's esophagus31921340 5. Other adenocarcinoma35067417 6. Adenosquamous carcinoma22527 7. Mucoepidermoid carcinoma202 8. Adenoid cystic carcinoma112 9. Endcrine cell carcinoma342458 10. Undifferentiated carcinoma7411 11. Others101323Other malignancies35843 1. Malignant non-epithelial tumors8210 2. Malignant melanoma20525 3. Other malignant tumors718Not specified000Total8135250310,638Resection: including endoscopic resection **Table 37** Malignant esophageal disease (clinical characteristics)Operation (+)EMR or ESDOperation (−)TotalCasesHospital mortality\~30 days31--90 daysTotal (including after 91 days mortality)1. Esophageal cancer624747 (0.8)46 (0.7)128 (2.0)1851249210,584Location (1) Cervical esophagus25801 (0.4)3 (1.2)76178512 (2) Thoracic esophagus504145 (0.9)39 (0.8)112 (2.2)150121338675 (3) Abdominal esophagus6442 (0.3)3 (0.5)7 (1.1)100117861 (4) Multiple cancers30103 (1.0)6 (2.0)17461536 (5) Others/not described3000030Tumor depth (A) Superficial cancer (T1)18929 (0.5)9 (0.5)22 (1.2)18482103950  *Mucosal cancer* (*T1a*)*41502* (*0.5*)*2* (*0.5*)*1514491978* (B) Advanced cancer (T2--T4)434437 (0.9)37 (0.9)105 (2.4)222826628 (C) Not specified111 (9.1)01 (9.1)10122. Multiple primary cancers10507 (0.7)7 (0.7)21 (2.0)52033819081) Synchronous5874 (0.7)2 (0.3)10 (1.7)210185982 (1) Head and neck184001 (0.5)8459327 (2) Stomach2262 (0.9)04 (1.8)7265363 (3) Others1441 (0.7)2 (1.4)4 (2.8)4142227 (4) Triple cancers331 (3.0)01 (3.0)131965 (5) Unknown00000002) Metachronous4633 (0.6)5 (1.1)11 (2.4)310153926 (1) Head and neck10201 (1.0)2 (2.0)10738247 (2) Stomach1142 (1.8)1 (0.9)3 (2.6)7536225 (3) Others2211 (0.5)2 (0.9)5 (2.3)8660367 (4) Triple cancers2601 (3.8)1 (3.8)421987 (5) Unknown0000000Unknown0000000Values in parenthesis represent mortality %*EMR* endoscopic mucosal resection (including endoscopic submucosal dissection) Fig. 3Annual trend of in-patients with esophageal diseases. *EMR* endoscopic mucosal resection (including endoscopic submucosal)

Among benign esophageal diseases (Table [35](#Tab50){ref-type="table"}), hiatal hernia, esophageal varices, esophagitis (including reflux esophagitis) and achalasia were the most common conditions in Japan. On the other hand, spontaneous rupture of the esophagus, benign esophageal tumors and congenital esophageal atresia were common diseases which were surgically treated as well as the above-mentioned diseases. The thoracoscopic and/or laparoscopic procedures have been widely adopted for benign esophageal diseases, in particular achalasia, hiatal hernia and benign tumors. Open surgery was performed in 1072 patients with a benign esophageal disease, with 30-day mortality in 14 (1.3 %), while thoracoscopic and/or laparoscopic surgery was performed for 588 patients, with 1(0.2 %) of the 30-day mortality The difference in these death rates between open and scopic surgery seems to be related the conditions requiring open surgery.

The majority of malignant diseases were carcinomas (Table [36](#Tab51){ref-type="table"}). Among esophageal carcinomas, the incidence of squamous cell carcinoma was 90.5 %, while that of adenocarcinomas including Barrett cancer was 7.1 %. The resection rate for patients with a squamous cell carcinoma was 76.4 %, while that for patients with an adenocarcinoma was 88.3 %.

According to location, cancer in the thoracic esophagus was the most common (Table [37](#Tab52){ref-type="table"}). Of the 3950 patients (37.3 % of total esophageal malignancies) having superficial esophageal cancers within mucosal and submucosal layers, 1892 (47.9 %) patients underwent esophagectomy, while 1848 (46.8 %) patients underwent EMR or ESD. The 30-day mortality rate and hospital mortality rate after esophagectomy for patients with a superficial cancer were 0.5 and 1.2 % respectively. Advanced esophageal cancer invading deeper than the submucosal layer was observed in 6628 (62.6 %) patients. Of the 6628 patients with advanced esophageal cancer, 4344 (65.5 %) underwent esophagectomy, with 0.9 % of the 30-day mortality rate, and with 2.4 % of the hospital mortality rate.

Multiple primary cancers were observed in 1908 (18.0 %) of all the 10,584 patients with esophageal cancer. Synchronous cancer was found in 982 (51.5 %) patients, while metachronous cancer (found before esophageal cancer) was observed in 926 (48.5 %) patients. The stomach is the commonest site for both synchronous and metachronous malignancy followed by head and neck cancer (Table [37](#Tab52){ref-type="table"}).

Among esophagectomy procedures, transthoracic esophagectomy through right thoracotomy was the most commonly adopted for patients with a superficial cancer as well as for those with an advanced cancer (Table [38](#Tab53){ref-type="table"}). Transhiatal esophagectomy commonly performed in Western countries was adopted in only 2.8 % of patients having a superficial cancer who underwent esophagectomy and in 1.6 % of those having an advanced cancer in Japan. The thoracoscopic and/or laparoscopic esophagectomy were adopted for 1134 patients (59.9 %) with a superficial cancer, and for 1666 patients (38.3 %) with an advanced cancer. The number of cases of thoracoscopic and/or laparoscopic surgery for superficial or advanced cancer has been increasing for these several years (Fig. [4](#Fig4){ref-type="fig"}).**Table 38** Malignant esophageal disease (surgical procedures)Operation (+)Thoracoscopic and/or laparscopic procedureEMR or ESDCasesHospital mortalityCasesHospital mortality\~30 days31--90 daysTotal (including after 91 days mortality)\~30 days31--90 daysTotal (including after 91 days mortality)Superficial cancer (T1)*18929* (0.5)*9* (0.5)*22* (1.2)*11343* (0.3)*7* (0.6)*14* (1.2)1848 *Mucosal cancer* (*T1a*)*41502* (0.5)*2* (0.5)*2230001514*Esophagectomy*18929* (0.5)*9* (0.5)*22* (1.2)*11343* (0.3)*7* (0.6)*14* (1.2)1848 (1) Transhiatal esophagectomy531 (1.9)1 (1.9)2 (3.8)4000 (2) Transthoracic (rt.) esophagectomy and reconstruction15795 (0.3)8 (0.5)17 (1.1)10372 (0.2)7 (0.7)13 (1.3) (3) Transthoracic (lt.) esophagectomy and reconstruction430007000 (4) Cervical esophageal resection and reconstruction3500016000 (5) Two-stage operation2700013000 (6) Others1553 (1.9)03 (1.9)571 (1.8)01 (1.8) (7) Not specified00000000Advanced cancer (T2--T4)Esophagectomy*434437* (0.9)*37* (0.9)*105* (2.4)*166611* (0.7)*11* (0.7)*32* (1.9)2 (1) Transhiatal esophagectomy6801 (1.5)1 (1.5)7000 (2) Transthoracic (rt.) esophagectomy and reconstruction366131 (0.8)26 (0.7)78 (2.1)15229 (0.6)10 (0.7)27 (1.8) (3) Transthoracic (lt.) esophagectomy and reconstruction1371 (0.7)2 (1.5)3 (2.2)14000 (4) Cervical esophageal resection and reconstruction1711 (0.6)2 (1.2)8 (4.7)351 (2.9)02 (5.7) (5) Two-stage operation841 (1.2)1 (1.2)4 (4.8)25000 (6) Others/not specified2233 (1.3)5 (2.2)11 (4.9)631 (1.6)1 (1.6)3 (4.8) (7) Not specified00000000(Depth not specified)*111* (9.1)*01* (9.1)*0000*1Combined resection of other organs*3306* (1.8)*4* (1.2)*13* (3.9) (1) Aorta2000 (2) Trachea, bronchus24001 (4.2) (3) Lung773 (3.9)2 (2.6)6 (7.8) (4) Others2273 (1.3)2 (0.9)6 (2.6)Unknown0000Salvage surgery*2624* (1.5)*4* (1.5)*10* (3.8)*5502* (3.6)*2* (3.6)26Values in parenthesis represent mortality % Fig. 4Annual trend of video-assisted esophagectomy for esophageal malignancy

Combined resection of the neighboring organs during resection of an esophageal cancer was performed in 330 patients (Tables [38](#Tab53){ref-type="table"}, [39](#Tab54){ref-type="table"}). Resection of the aorta together with the esophagectomy was performed in 2 cases. Tracheal and/or bronchial resection combined with esophagectomy was performed in 24 patients, with the 30-day mortality rate at 0 % and the hospital mortality rate at 4.2 %. Lung resection combined with esophagectomy was performed in 77 patients, with the 30-day mortality rate at 3.9 % and the hospital mortality rate at 7.8 %.**Table 39**Mortality after combined resection of the neighboring organsYearEsophagectomyCombined resectionAortaTracheobronchusLungOthersabc (%)abc (%)abc (%)abc (%)abc (%)199641941202.867342.862400.005024.007845.13199744411272.86100.0034514.715611.799433.19199848781362.79400.002900.007411.3512821.56199950151162.31500.002328.706800.0012210.8220005350811.51200.002328.706900.009611.04200155211101.99100.002613.858333.619922.0220024904661.353133.3320210.006300.006311.5920034639450.97000.002428.335800.008811.1420044739641.35200.001700.005958.4711921.6820055163521.01100.001119.096711.497311.3720065236631.20000.001700.006223.2312232.4620074990601.20000.002514.004412.2713821.4520085124631.23000.001715.884812.0818500.0020095260631.20000.0019210.535823.4521131.4220105180450.87200.003300.005800.0024552.0420115430380.70400.002600.004100.0017952.7920126055470.78200.002314.356900.0024010.4220135824410.70200.004400.007711.3015631.9220146247470.75200.002400.007733.9022731.32Total98,19013841.4138410.53273207.331181231.952663431.61*a* The number of patients who underwent the operation, *b* number of patients died within 30 days after operation, *c* % ratio of b/a, i.e., direct operative mortality

Salvage surgery after definitive (chemo-) radiotherapy was performed in 262 patients, with the 30-day mortality rate at 1.5 % and with the hospital mortality rate at 3.8 % (Table [38](#Tab53){ref-type="table"}).

Last, in spite of the efforts of the Committee to cover wider patient populations to this annual survey, the majority of the institutions which responded to the questionnaire were the departments of thoracic or esophageal surgery. It should be noted that larger number of patients with esophageal diseases should have been treated medically and endoscopically. We should continue our effort for complete survey through more active collaboration with the Japan Esophageal Society and other-related societies.
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